




(86) **Date de dépôt PCT/PCT Filing Date:** 2000/04/05
(87) **Date publication PCT/PCT Publication Date:** 2000/10/12
(45) **Date de délivrance/Issue Date:** 2016/07/05
(85) **Entrée phase nationale/National Entry:** 2001/09/21
(86) **N° demande PCT/PCT Application No.:** US 2000/009021
(87) **N° publication PCT/PCT Publication No.:** 2000/060050
(30) **Priorités/Priorities:** 1999/04/06 (US60/127,912);
1999/05/06 (US60/132,839)

(51) **Cl.Int./Int.Cl. C12N 5/10** (2006.01),
C07K 14/11 (2006.01), **C12N 15/44** (2006.01),
C12N 15/85 (2006.01), **C12N 15/86** (2006.01),
C12N 7/00 (2006.01), **C12N 7/01** (2006.01),
C12N 7/04 (2006.01)
(72) **Inventeurs/Inventors:**
KAWAOKA, YOSHIHIRO, US;
NEUMANN, GABRIELE, US
(73) **Propriétaire/Owner:**
WISCONSIN ALUMNI RESEARCH FOUNDATION, US
(74) **Agent:** SMART & BIGGAR

(54) **Titre : VIRUS DE L'INFLUENZA RECOMBINANTS POUR VACCINS ET TRAITEMENT GENETIQUE**
(54) **Title: RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENE THERAPY**



(57) **Abrégé/Abstract:**

The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus and a method to prepare segmented, negative strand RNA viruses, e.g. orthomyxoviruses, entirely from cloned cDNA.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 October 2000 (12.10.2000)

PCT

(10) International Publication Number
WO 00/60050 A3(51) International Patent Classification⁷: C12N 7/00,
C07K 14/11, C12N 5/10, 15/63, 15/87

(21) International Application Number: PCT/US00/09021

(22) International Filing Date: 5 April 2000 (05.04.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/127,912 6 April 1999 (06.04.1999) US
60/132,839 6 May 1999 (06.05.1999) US(71) Applicant (for all designated States except US): **WISCONSIN ALUMNI RESEARCH FOUNDATION**
[US/US]; 614 Walnut Street, Madison, WI 53705 (US).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **KAWAOKA, Yoshihiro** [JP/US]; 8722 Airport Road, Middleton, WI 53562 (US). **NEUMANN, Gabriele** [DE/US]; 6810 Schroeder Road, Apartment 18, Madison, WI 53711 (US).(74) Agent: **VIKSINS, Ann, S.**; Schwegman, Lundberg, Woessner & Kluth, P.O. Box 2938, Minneapolis, MN 55402 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

[Continued on next page]

(54) Title: RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENE THERAPY



(57) Abstract: The invention provides a composition useful to prepare influenza A viruses, e.g., in the absence of helper virus and a method to prepare segmented, negative strand RNA viruses, e.g. orthomyxoviruses, entirely from cloned cDNA.

WO 00/60050 A3

WO 00/60050 A3



(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:
18 January 2001

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— *With international search report.*

RECOMBINANT INFLUENZA VIRUSES FOR VACCINES AND GENE THERAPY

Statement of Government Rights

5 This invention was made with a grant from the Government of the United States of America (grant AI-29599 from the National Institute of Allergy and Infectious Diseases Public Health Service). The Government may have certain rights in the invention.

Background of the Invention

10 The ability to generate infectious RNA viruses from cloned cDNAs has contributed greatly to the biological understanding of these pathogens and hence to improved methods of disease control (Palese et al., 1996). However, this progress had been relatively limited for negative-sense as compared with
15 positive-sense RNA viruses, because neither the genomic viral RNA (vRNA) nor the antigenomic complementary RNA (cRNA) of negative-sense RNA viruses can serve as a direct template for protein synthesis. Rather, the vRNA, after its encapsidation by viral nucleoprotein (NP), must be transcribed into positive-sense mRNA by the viral RNA polymerase complex. Thus, the minimal
20 replication unit is formed by the genomic vRNA complexed with NP and the polymerase proteins. Despite these obstacles, reverse genetics methods have been established to produce nonsegmented negative-sense RNA viruses, including rabies virus (Snell et al., 1994), vesicular stomatitis virus (Lawson et al., 1995); Whelan et al., 1995), measles virus (Radecke et al., 1995), respiratory
25 syncytial virus (Collins et al., 1995), Sendai virus (Garcin et al., 1995; Kato et al., 1996), rinderpest virus (Baron et al., 1997), human parainfluenza virus type 3 (Hoffman et al., 1997) and SV5 (He et al., 1997).

 The *Orthomyxoviridae*, *Arenaviridae*, and *Bunyaviridae* families contain segmented, negative strand RNA genomes and include several human and
30 animal pathogens, for example, influenza virus types A, B, and C (*Orthomyxoviridae*), lymphocytic choriomeningitis virus (LCMV) (*Arenaviridae*), and encephalitic and hemorrhagic fever viruses (*Bunyaviridae*, *Arenaviridae*). Their genomes consist of two (*Arenaviridae*), three

(*Bunyaviridae*), or six to eight (*Orthomyxoviridae*) single-stranded RNA molecules of negative polarity (complementary to mRNA). The vRNAs interact with NP and viral RNA-dependent RNA-polymerase to form ribonucleoprotein complexes (RNPs). The RNPs are surrounded by a lipid bilayer derived from the host cell. Inserted in this envelope are viral glycoproteins, which are essential for receptor binding and entry into the host cell. Thus, generating segmented negative-sense RNA viruses from cloned cDNAs poses a formidable challenge, as one must produce a separate vRNA for each gene segment.

Bridgen and Elliott (1996) produced a Bunyamwera virus (family *Bunyaviridae*) from cloned cDNAs encoding three segments of antigenomic, positive-sense vRNA. However, the efficiency of virus recovery was low. None of the orthomyxoviruses, which contain six (thogotovirus), seven (influenza C virus) or eight (influenza A and B viruses) segments of negative-sense RNA have been produced entirely from cloned cDNAs. This lag in progress has been felt most acutely in efforts to control influenza virus infections.

Palese and colleagues (Enami et al., 1990) pioneered the reverse genetics, helper virus-dependent system for influenza A virus (Figure 1A). In their approach, RNP complexes are generated by *in vitro* vRNA synthesis in the presence of purified polymerase and NP proteins, and then used to transfect eukaryotic cells. Subsequent infection with influenza A helper virus results in the generation of viruses possessing a gene derived from cloned cDNA. A second method, developed by Neumann et al. (1994), is based on the *in vivo* synthesis of vRNA by RNA polymerase I (Figure 1B), a cellular enzyme that transcribes ribosomal RNA that lacks both a 5' cap and a 3' polyA tail. Cells infected with influenza virus and transfected with a plasmid containing cloned influenza virus cDNA, flanked by murine RNA polymerase I promoter and terminator sequences, led to the production of transfectant viruses. With both methods, however, transfectants must be selected from a vast background of helper viruses, which requires a strong selection system and complicates the generation of growth-defective viruses.

A system to generate replication-incompetent virus-like particles (VLPs) was developed by Mena et al. (1996), in which an influenza virus-like vRNA

encoding a reporter gene is transcribed *in vitro* and transfected into eukaryotic cells. All ten influenza virus proteins are expressed from plasmids under the control of a T7 RNA polymerase promoter. When the transfected cells are infected with a recombinant vaccinia virus that expressed T7 RNA polymerase, they produced influenza VLPs.

5 However, the efficiency of the system is low: in 25% of the experiments, the investigators failed to detect reporter gene expression. Moreover, vaccinia virus expresses more than 80 proteins, any of which could affect the influenza viral life cycle.

Thus, what is needed is a method to prepare segmented, negative strand RNA viruses, e.g., orthomyxoviruses such as influenza A viruses, entirely from cloned cDNAs.

10

Summary of the Invention

In one aspect, the invention provides at least one of the following isolated and purified vectors: a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination
 15 sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter
 20 operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, and a vector comprising a operably linked to an influenza virus NS cDNA linked to a transcription termination sequence. The cDNA may be in the sense or antisense orientation relative to the promoter. Thus, a
 25 vector of the invention may encode an orthomyxovirus protein (sense), or vRNA (antisense). Any promoter may be employed to express a viral protein. Preferred promoters for the vectors encoding vRNA include, but are not limited to, a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T7 promoter, and a T3 promoter. It is further preferred that the RNA polymerase I

promoter is a human RNA polymerase I promoter. Preferred transcription termination sequences for the vectors encoding vRNA include, but are not limited to, a RNA polymerase I transcription termination sequence, a RNA polymerase II transcription termination sequence, or a RNA polymerase III transcription termination sequence, or a ribozyme. Preferably, the vectors

5 comprise influenza cDNA, e. g., influenza A (e.g., any influenza A gene including any of the 15 HA or 9 NA subtypes), B or C DNA (see Chapters 45 and 46 of Fields Virology (Fields et al. (eds.), Lippincott-Raven Publ., Philadelphia, PA (1996), although it is envisioned that the gene (s) of any virus may be employed in the vectors or methods of the invention.

A promoter for the vectors comprising influenza virus cDNA may include a RNA

10 polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T7 promoter, and a T3 promoter. Each vector comprising influenza virus cDNA may comprise a transcription termination sequence such as a RNA polymerase I transcription termination sequence, a RNA polymerase II transcription termination sequence, or a RNA polymerase III transcription termination sequence, or a ribozyme. The vectors may comprise influenza DNA,

15 e. g., influenza A, B or C DNA.

Compositions of the invention as described herein may further comprise a vector comprising a promoter linked to 5' orthomyxovirus non-coding sequences linked to a desired cDNA linked to 3' orthomyxovirus non-coding sequences linked to transcription termination sequences. The introduction of such a composition to a host cell permissive for orthomyxovirus

20 replication results in recombinant virus comprising vRNA corresponding to sequences of the vector comprising 5' orthomyxovirus non- coding sequences linked to a cDNA linked to 3' orthomyxovirus non-coding sequences. Preferably, the cDNA is in an antisense orientation. Also preferably, the promoter is a RNA polymerase I promoter, a RNA polymerase II promoter, a RNA polymerase III promoter, a T7 promoter, and a T3 promoter. It is also preferred that the

25 transcription termination sequence is a RNA polymerase I transcription termination sequence, a RNA polymerase II transcription termination sequence, or a RNA polymerase III transcription termination sequence, or a ribozyme. For example, the cDNA may encode an immunogenic epitope, such as an epitope useful in a cancer therapy or vaccine.

A plurality of the vectors of the invention may be physically linked or each vector may be present on an individual plasmid or other, e. g., linear, nucleic acid delivery vehicle.

The invention also provides a method to prepare recombinant influenza virus. The method comprises transfecting a cell with a composition as described herein, in an amount effective to yield infectious recombinant influenza virus. The invention may also include isolating the virus. As well, the invention provides a method to prepare a gene delivery vehicle, comprising: transfecting cells with the composition as described herein in an amount effective to yield recombinant influenza virus, and isolating the virus.

Thus, in one aspect, the invention provides a method to prepare a gene delivery vehicle.

The method comprises: transfecting cells with a plurality of orthomyxovirus vectors, which are sufficient to produce infectious influenza viruses in a host cell in the absence of helper virus, the vectors comprising: a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PA cDNA linked to a RNA polymerase I transcription termination sequence, a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PB1 cDNA linked to a RNA polymerase I transcription termination sequence, a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PB2 cDNA linked to a RNA polymerase I transcription termination sequence, a vector comprising a RNA polymerase I promoter operably linked to an influenza virus NP cDNA linked to a RNA polymerase I transcription termination sequence, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1 polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2 polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NP polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus HA polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NA polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus M1 polypeptide, a vector comprising a promoter operably

linked to a DNA segment encoding an influenza virus M2 polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NS2 polypeptide, and a vector comprising a RNA polymerase I promoter linked to 5' non-coding influenza virus sequences linked to an antisense cDNA linked to 3' non-coding influenza virus sequences linked to a RNA
 5 polymerase I transcription termination sequence, and isolating the infectious influenza virus.

In another aspect, the invention provides a method for producing infectious recombinant influenza virus in the absence of helper virus, comprising the step of introducing into a cell a composition comprising a plurality of orthomyxovirus vectors, which are sufficient to produce infectious recombinant influenza viruses, the vectors comprising: (i) a vector comprising a promoter
 10 operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a
 15 vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a
 20 transcription termination sequence, (ii) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA, (iii) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1, (iv) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2, and (v) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP.

25 The vectors may further comprise: (vi) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA, (vii) a vector comprising a

promoter operably linked to a DNA segment encoding influenza virus NA, (viii) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M1, (ix) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M2, and (x) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

5 Thus, in other aspects, the invention further provides an infectious recombinant influenza virus obtained by a method of the invention, as well as a host cell transfected with the composition or infectious recombinant influenza virus as described herein.

Thus, in one aspect, the invention provides a cell transfected with a plurality of orthomyxovirus vectors, the vectors comprising: a vector comprising a promoter operably linked to
 10 an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector comprising a promoter
 15 operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence, a
 20 vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1 polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2 polypeptide, a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NP polypeptide, and a vector comprising a promoter
 25 linked to 5' non-coding influenza virus sequences linked to an antisense cDNA of interest or a fragment thereof in antisense orientation linked to 3' non-coding influenza virus sequences linked to a transcription termination sequence,

wherein the cell transfected does not comprise a helper virus, and wherein said preparation is isolated from said cells.

In yet another aspect, the invention provides use of an effective amount of the infectious recombinant influenza virus or virus preparation of the invention, including in the manufacture of a medicament, for immunizing an individual against a pathogen.

In yet another aspect, the invention provides use of the infectious recombinant influenza virus or virus preparation of the invention for gene therapy or a vaccine, including in the manufacture of a medicament for gene therapy or in the manufacture of a vaccine.

In other aspects, the invention provides the infectious recombinant influenza virus or virus preparation of the invention for use in immunizing an individual against a pathogen, for use in gene therapy, or for use in a vaccine.

As described hereinbelow, influenza A viruses were prepared entirely from cloned cDNAs. The reverse genetics approach described herein is highly efficient and can be used to introduce mutations into any gene segment and to develop influenza virus-based gene delivery systems. For example, human embryonic kidney cells (293T) were transfected with eight plasmids, each encoding a viral RNA of the A/WSN/33 (H1N1) or A/PR/8/34 (H1N1) virus, flanked by the human RNA polymerase I promoter and the mouse RNA polymerase I terminator, together with plasmids encoding viral nucleoprotein and the PB2, PB1 and PA viral polymerases. This strategy yields $> 1 \times 10^3$

plaque-forming units (pfu) of virus per ml of supernatant at 48 hours post-transfection. Depending on the virus generated, the addition of plasmids expressing all of the remaining viral structural proteins led to a substantial increase in virus production, $> 3 \times 10^4$ pfu/ml. Reverse genetics was also
5 employed to generate a reassortant virus containing the PB1 gene of the A/PR/8/34 virus, with all other genes representing A/WSN/33. Additional viruses produced by this method had mutations in the PA gene or possessed a foreign epitope in the head of the neuraminidase protein.

Moreover, the same approach may be employed for other viruses to
10 generate nonsegmented negative strand RNA viruses (i.e., Paramyxoviridae, Rhabdoviridae, and Filoviridae), or other segmented negative strand RNA viruses, e.g., Arenaviridae and Bunyaviridae, entirely from cloned cDNA. Further, the expression of cRNA in cells instead of vRNA may improve the efficiency of virus generation.

15 The method of the invention allows easy manipulation of influenza viruses, e.g., by the introduction of attenuating mutations into the viral genome. Further, because influenza viruses induce strong humoral and cellular immunity, the invention greatly enhances these viruses as vaccine vectors, particularly in view of the availability of natural variants of the virus, which may be employed
20 sequentially, allowing repetitive use for gene therapy.

Thus, the invention provides isolated and purified vectors or plasmids, which express or encode influenza virus proteins, or express or encode influenza vRNA, both native and recombinant vRNA. Thus, a vector or plasmid of the invention may comprise a gene or open reading frame of interest, e.g., a foreign
25 gene encoding an immunogenic peptide or protein useful as a vaccine. Preferably, the vector or plasmid which expresses influenza vRNA comprises a promoter, e.g., a RNA polymerase I, suitable for expression in a particular host cell, e.g., avian or mammalian host cells such as canine, feline, equine, bovine, ovine, or primate cells including human cells. Also preferably, the vectors or
30 plasmids comprising DNA useful to prepare influenza vRNA comprise RNA polymerase I transcription termination sequences. For vectors or plasmids comprising a gene or open reading frame of interest, it is preferred that the gene or open reading frame is flanked by the 5' and 3' non-coding sequences of

Therefore, the invention also provides for a host cell, the genome of which is stably augmented with at least one recombinant DNA molecule. The recombinant DNA molecule includes at least one of the following: a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus HA coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus NA coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus M1 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus NS2 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus M2 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first

loxP site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus PA coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus PB1 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus PB2 coding region; or a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop or termination sequence linked to a second *lox* site linked to an influenza virus NP coding region.

Preferably, the host cell is augmented with a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus HA coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus NA coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus M1 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus NS2 coding region; and a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus M2 coding region. Preferably, the *lox* sites are *loxP* sites.

The invention also provides a method to prepare infectious replication defective influenza virus. The method comprises contacting a host cell which is augmented with at least one recombinant DNA molecule of the invention, e.g.,

encoding HA, NA, M1, M2, NS2, PA, PB1, PB2, or NP, with a recombinant influenza virus comprising: vRNA comprising a Cre open reading frame, and vRNAs comprising influenza genes not expressed by the host cell. Virus is then recovered from the contacted host cell. Preferably, the recombinant virus further comprises vRNA comprising a desired open reading frame. Alternatively, the augmented host cell is contacted with a vector comprising a promoter functional in the host cell operably linked to a DNA segment encoding Cre, and a plurality of vectors each comprising a promoter operably linked to an influenza virus cDNA not present in the host cell. Virus is then recovered.

10 The invention also provides a host cell, the genome of which is augmented with a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to a host cell surface binding protein coding region; a recombinant DNA molecule comprising
15 a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to a fusion protein coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second
20 *lox* site linked to an influenza virus M1 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus NS2 coding region; and a recombinant DNA molecule comprising a promoter functional in the host cell
25 linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus M2 coding region. Preferably, the *lox* sites are *loxP* sites.

Yet another embodiment is a host cell, the genome of which is augmented with a recombinant DNA molecule comprising a promoter functional
30 in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to a host cell surface binding and fusion protein coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked

to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus M1 coding region; a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to
5 a second *lox* site linked to an influenza virus NS2 coding region; and a recombinant DNA molecule comprising a promoter functional in the host cell linked to a first *lox* site linked to a DNA segment comprising a transcription stop sequence linked to a second *lox* site linked to an influenza virus M2 coding region. Preferably, the *lox* sites are *loxP* sites.

10 Host cells augmented with recombinant DNA molecules as described hereinabove are useful to prepare infectious replication defective influenza virus. For example, a host cell stably transformed with recombinant DNA molecules encoding HA, NA, M1, M2 and NS2 is contacted with a plurality of vectors, i.e., vectors which express vRNA comprising a Cre open reading frame, vRNA
15 comprising PA, vRNA comprising NP, vRNA comprising PB1, vRNA comprising PB2, and optionally, vRNA comprising a gene of interest; and vectors which encode PA, PB1, PB2, and NP.

The methods of producing virus described herein, which do not require helper virus infection, are useful in viral mutagenesis studies, and in the
20 production of vaccines (e.g., for AIDS, influenza, hepatitis B, hepatitis C, rhinovirus, filoviruses, malaria, herpes, and foot and mouth disease) and gene therapy vectors (e.g., for cancer, AIDS, adenosine deaminase, muscular dystrophy, ornithine transcarbamylase deficiency and central nervous system tumors).

25 Thus, a virus for use in medical therapy (e.g., for a vaccine or gene therapy) is provided. For example, the invention provides a method to immunize an individual against a pathogen, e.g., a bacteria, virus, or parasite, or a malignant tumor. The method comprises administering to the individual an amount of at least one isolated virus of the invention, optionally in combination
30 with an adjuvant, effective to immunize the individual. The virus comprises vRNA comprising a polypeptide encoded by the pathogen or a tumor specific polypeptide.

Also provided is a method to augment or increase the expression of an endogenous protein in a mammal having an indication or disease characterized by a decreased amount or a lack of the endogenous protein. The method comprises administering to the mammal an amount of an isolated virus of the invention effective to augment or increase the amount of the endogenous protein in the mammal. Preferably, the mammal is a human.

The invention also provides vectors and methods for the recombinant production of positive strand viruses, e.g., positive-sense RNA viruses. Thus, the invention provides a vector comprising a DNA segment comprising RNA polymerase I transcription initiation sequences operably linked to a second DNA segment comprising sequences from a positive-sense RNA virus, optionally operably linked to a third DNA segment comprising RNA polymerase I transcription termination sequences. Also provided is a method of using the vector(s) to prepare recombinant virus. The method is particularly useful as it employs cloned DNA and transfection techniques, thus circumventing RNA handling. Moreover, RNA polymerase I transcription is highly efficient and has high fidelity. For positive-sense RNA viruses whose genomic RNA is uncapped (e.g., pestiviruses; hepatitis C virus; and Picornaviridae, including poliovirus, rhinoviruses, hepatitis A virus, and foot and mouth disease virus), a cDNA encoding the full-length genome is introduced in genomic-sense orientation between RNA polymerase I promoter and terminator sequences. Transfection of the resulting plasmid into permissive host cells yields genomic RNA for virus replication. A number of positive-sense RNA viruses contain capped genomic RNAs (e.g., flaviviruses, including dengue fever virus and several encephalitis viruses). While RNA polymerase I transcripts are not capped, a cDNA encoding the full-length genome of RNA viruses having capped genomic RNAs is introduced in antigenomic-sense orientation in a RNA polymerase I transcription vector. Following transfection of the resulting plasmid, cellular RNA polymerase I transcribes an antigenomic (uncapped) RNA. Moreover, cotransfection with protein expression plasmids for the proteins required for replication results in the replication of the antigenomic RNA, hence yielding genomic RNA and ultimately infectious virus.

Brief Description of the Drawings

Figure 1. Schematic diagram of established reverse genetics systems. In the RNP transfection method (A), purified NP and polymerase proteins are assembled into RNPs with use of *in vitro*-synthesized vRNA. Cells are transfected with RNPs, followed by helper virus infection. In the RNA polymerase I method (B), a plasmid containing the RNA polymerase I promoter, a cDNA encoding the vRNA to be rescued, and the RNA polymerase I terminator is transfected into cells. Intracellular transcription by RNA polymerase I yields synthetic vRNA, which is packaged into progeny virus particles upon infection with helper virus. With both methods, transfectant viruses (i.e., those containing RNA derived from cloned cDNA), are selected from the helper virus population.

Figure 2. Schematic diagram of the generation of RNA polymerase I constructs. cDNAs derived from influenza virus were amplified by PCR, digested with *Bsm*BI and cloned into the *Bsm*BI sites of the pHH21 vector (E. Hoffmann, Ph.D. thesis, Justus, Liebig-University, Giessen, Germany), which contains the human RNA polymerase I promoter (P) and the mouse RNA polymerase I terminator (T). The thymidine nucleotide upstream of the terminator sequence (*T) represents the 3' end of the influenza viral RNA. Influenza A virus sequences are shown in bold face letters.

Figure 3. Proposed reverse genetics method for generating segmented negative-sense RNA viruses. Plasmids containing the RNA polymerase I promoter a cDNA for each of the eight viral RNA segments, and the RNA polymerase I terminator are transfected into cells together with protein expression plasmids. Although infectious viruses can be generated with plasmids expressing PA, PB1, PB2, and NP, expression of all remaining structural proteins (shown in brackets) increases the efficiency of virus production depending on the virus generated.

Figure 4. Detection of the FLAG epitope in cells infected with a transfectant virus. Antibody staining was used to identify the NA in MDCK cells infected with either PR8-WSN-FL79 (A, D) or A/WSN/33 wild-type virus (B, E), or on mock-infected MDCK cells (C, F). Nine hours after infection, cells

were fixed with paraformaldehyde, treated with Triton X-100™ and incubated with either anti-FLAG (A-C) or anti-WSN NA (D-F) monoclonal antibodies. Intensive *Golgi* staining (red) is apparent in positive samples (A, D, and E).

Figure 5. Recovery of PA mutants. The PA gene of each virus was amplified by RT-PCR with primers that yield a 1226 bp fragment (position 677 to 1903 of the mRNA, lanes 1,3,5), which was then digested with the restriction enzyme *Bsp*120I (at position 846 of the mRNA, lanes 4,7) or *Pvu*II (at position 1284 of the mRNA, lanes 2,6). The presence of *Bsp*120I or *Pvu*II sites in the PCR products yielded either 169 bp and 1057 bp or 607 bp and 619 bp fragments, respectively. MW = molecular weight markers.

Figure 6. Primers employed to amplify influenza sequences.

Figure 7. The pPoll-GFP plasmid for generating influenza virus-like RNA encoding the GFP protein. This plasmid contains the GFP gene (derived from pEGFP-N1; Clontech, Palo Alto, CA) in antisense orientation between the 5' and 3' noncoding regions of influenza A virus segment 5, flanked by the human RNA polymerase I promoter and the mouse RNA polymerase I terminator.

Figure 8. Schematic diagram of VLP generation strategy. Individual protein expression plasmids and a plasmid containing the RNA polymerase I promoter, a cDNA encoding the GFP reporter gene, and the RNA polymerase I terminator are transfected into 293T cells. Intracellular transcription by RNA polymerase I yields GFP vRNA of negative polarity, as indicated by inverted letters. Supernatants containing VLPs are harvested, mixed with influenza helper virus and inoculated into MDCK cells.

Figure 9. The PA, PB 1, PB2, and NP proteins of influenza A virus encapsidate GFP vRNA produced by RNA polymerase I, leading to GFP expression. 293T cells were transfected with plasmids expressing the PB2, PB 1, PA and NP proteins (A) or with all plasmids except the one expressing the NP protein (B), together with the RNA polymerase I-GFP gene plasmid for intracellular synthesis of reporter gene vRNA. Cells were fixed 48 h after transfection, and GFP expression was determined with a fluorescence microscope.

30

Figure 10. Generation of infectious influenza VLPs. 293T cells were transfected with nine plasmids, each expressing a different viral structural protein (A), or with eight plasmids omitting the construct for NP (B), together with the RNA polymerase I-GFP gene plasmid. Forty-eight hours after
5 transfection, VLP-containing supernatants were collected, mixed with A/WSN/33 helper virus, and inoculated into MDCK cells. Cells were fixed at 10 hours after infection, and GFP expression was determined with a fluorescence microscope.

Figure 11. Schematic of the use of Cre recombinase to express influenza
10 NS2 protein in a cell, the genome of which is augmented with a recombinant DNA molecule. The genome of the cell comprises a recombinant DNA molecule which comprises a promoter linked to a site specific recombination site (e.g., *loxP*) linked to a transcription stop sequence linked to a second site specific recombination site in the same orientation as the first site specific recombination
15 site linked to the NS2 gene.

Figure 12. Preparation of replication defective influenza virus.

Detailed Description of the Invention

Definitions

20 As used herein, the terms "isolated and/or purified" refer to *in vitro* preparation, isolation and/or purification of a vector or plasmid of the invention, so that it is not associated with *in vivo* substances, or is substantially purified from *in vitro* substances. As used herein, the term "recombinant nucleic acid" or "recombinant DNA sequence or segment" refers to a nucleic acid, e.g., to DNA,
25 that has been derived or isolated from a source, that may be subsequently chemically altered *in vitro*, so that its sequence is not naturally occurring, or corresponds to naturally occurring sequences that are not positioned as they would be positioned in the native genome. An example of DNA "derived" from a source, would be a DNA sequence that is identified as a useful fragment, and
30 which is then chemically synthesized in essentially pure form. An example of such DNA "isolated" from a source would be a useful DNA sequence that is excised or removed from said source by chemical means, e.g., by the use of

restriction endonucleases, so that it can be further manipulated, e.g., amplified, for use in the invention, by the methodology of genetic engineering.

As used herein, "site-specific recombination" is intended to include the following three events: 1) deletion of a target DNA segment flanked by site-specific recombination sites or sequences, e.g., *loxP* sites; 2) inversion of the nucleotide sequence of a target DNA segment flanked by site-specific recombination sites or sequences, e.g., *lox* sites; and 3) reciprocal exchange of target DNA segments proximate to site-specific recombination sites or sequences, e.g., *lox* sites located on different DNA molecules. Site-specific recombinase systems include, but are not limited to, the Cre/*loxP* system of bacteriophage P1 (U.S. Patent No. 5,658,772).

To remedy the reversibility of a site-specific recombination reaction, the structure of the recombination system may be altered. The site-specific recombination sequence can be mutated in a manner that the product of the recombination reaction is no longer recognized as a substrate for the reverse reaction, thereby stabilizing the integration or excision event. For example, to remove undesired sequences, *lox* sites in the same orientation are positioned to flank the undesired sequences.

Other *lox* sites include *loxB*, *loxL*, and *loxR* sites which are nucleotide sequences isolated from *E. coli* (Hoess et al., Proc. Natl. Acad. Sci. USA, **79**, 3398 (1982)). *Lox* sites can also be produced by a variety of synthetic techniques which are known in the art. For example, synthetic techniques for producing *lox* sites are disclosed by Ito et al., Nuc. Acid Res., **10**, 1755 (1982) and Ogilvie et al., Science, **214**, 270 (1981).

As used herein, the expression "*lox* site" means a nucleotide sequence at which the gene product of the *cre* gene can catalyze a site-specific recombination. *LoxP* is a 34 base pair nucleotide sequence which can be isolated from bacteriophage P1 by methods known in the art (see, for example, Hoess et al., Proc. Natl. Acad. Sci. USA, **79**, 3398 (1982)). *LoxP* consists of two 13 base pair inverted repeats separated by an 8 base pair spacer region.

As used herein, the expression "*cre* gene" means a nucleotide sequence which codes for an enzymic gene product which effects site-specific recombination of DNA in eukaryotic cells at *lox* sites. A *cre* gene can be

isolated from bacteriophage P1 by methods known in the art (see Abremaid et al., *Cell*, 32, 1301-1311 (1983)).

Influenza virus replication

Influenza A viruses possess a genome of eight single-stranded negative-sense viral RNAs (vRNAs) that encode a total of ten proteins. The influenza virus life cycle begins with binding of the hemagglutinin (HA) to sialic acid-containing receptors on the surface of the host cell, followed by receptor-mediated endocytosis. The low pH in late endosomes triggers a conformational shift in the HA, thereby exposing the N-terminus of the HA2 subunit (the so-called fusion peptide). The fusion peptide initiates the fusion of the viral and endosomal membrane, and the matrix protein (M1) and RNP complexes are released into the cytoplasm. RNPs consist of the nucleoprotein (NP), which encapsidates vRNA, and the viral polymerase complex, which is formed by the PA, PB1, and PB2 proteins. RNPs are transported into the nucleus, where transcription and replication take place. The RNA polymerase complex catalyzes three different reactions: synthesis of an mRNA with a 5' cap and 3' polyA structure, of a full-length complementary RNA (cRNA), and of genomic vRNA using the cDNA as a template. Newly synthesized vRNAs, NP, and polymerase proteins are then assembled into RNPs, exported from the nucleus, and transported to the plasma membrane, where budding of progeny virus particles occurs. The neuraminidase (NA) protein plays a crucial role late in infection by removing sialic acid from sialyloligosaccharides, thus releasing newly assembled virions from the cell surface and preventing the self aggregation of virus particles. Although virus assembly involves protein-protein and protein-vRNA interactions, the nature of these interactions is largely unknown.

Thogotovirus

Thogotoviruses (THOV) represent a new genus in the family of *Orthomyxoviridae*. They are transmitted by ticks and have been found in domestic animals, including camels, goats, and cattle. Consequently, THOV can replicate in tick and vertebrate cells. The THOV genome comprises six segments of single-stranded, negative-sense RNA. The proteins encoded by the three largest segments show significant homology to the influenza virus

polymerase proteins PB2, PB1, and PA. Segment 5 encodes a protein related to influenza virus NP. The THOV glycoprotein, which is encoded by segment 4, is not homologous to either influenza virus HA or NA, but it shows sequence similarity to the Baculovirus glycoprotein. The smallest segment is thought to
5 encode a matrix protein and does not resemble any of the influenza virus proteins. Like influenza virus, both the 3' and 5' ends of the vRNA are required for promoter activity, and this activity is located in the terminal 14 and 15 nucleotides of the 3' and 5' ends of the vRNA, respectively.

The mRNA synthesis of THOV is primed by host cell-derived cap
10 structures. However, in contrast to influenza virus, only the cap structures (without additional nucleotides) are cleaved from cellular mRNAs (Albo et al., 1996; Leahy et al., 1997; Weber et al., 1996). *In vitro* cleavage assays revealed that both the 5' and 3' ends of vRNA are required for endonuclease activity (Leahy et al., 1998), but addition of a model cRNA promoter does not stimulate
15 endonuclease activity (Leahy et al., 1998), as has been shown for influenza virus (Cianci et al., 1995; Hagen et al., 1994). A 'hook' structure has been proposed for THOV (Leahy et al., 1997; Weber et al., 1997), which is similar to the corkscrew structure proposed for influenza virus (Flick et al., 1996). This 'hook' structure, however, is only found in the THOV vRNA promoter. The cRNA
20 promoter sequence does not allow the formation of base pairs between positions 2 and 9, and between 3 and 8 at the 5' end of the cRNA. Alterations at positions 3 or 8 to allow base-pairing between these nucleotides stimulates endonuclease activity, which is strong supporting evidence of the proposed 'hook' structure (Leahy et al., 1998). Moreover, this structure might be crucial for the regulation
25 of the THOV life cycle; the vRNA promoter, forming the 'hook' structure, may stimulate PB2 endonuclease activity, thereby allowing transcription. The cRNA promoter, in contrast, may not form the 'hook' structure and may therefore be unable to stimulate endonuclease activity, thus resulting in replication.

Bunyaviridae

30 The family *Bunyaviridae* includes several viruses that cause hemorrhagic or encephalitic fevers in humans (e.g., Rift fever valley, Hantaan, La Crosse, and Crimean-Congo hemorrhagic fever). The spherical and enveloped virions contain three segments of single-stranded, negative-sense RNA (reviewed in

Elliott, 1997). The largest segment (L) encodes the viral RNA polymerase protein (L protein), whereas the M segment encodes the two viral glycoproteins G1 and G2, and a nonstructural protein (NSm). The smallest segment (S) encodes the nucleocapsid protein (N) and a second nonstructural protein (NSs).

- 5 Virus replication and transcription take place in the cytoplasm, and newly assembled virions bud through the membranes of the Golgi apparatus.

Bridgen & Elliott (1996) have established a reverse genetics system to generate infectious Bunyamwera virus entirely from cloned cDNAs. They followed a strategy first described by Schnell et al. (1994) for rabies virus:

- 10 intracellular transcription of a cDNA coding for the positive-sense antigenomic RNA (but not for the negative-sense genomic RNA) in cells expressing the viral polymerase and nucleoprotein. Bridgen & Elliott (1996) infected HeLaT4+ cells with vaccinia virus expressing T7 polymerase and transfected these cells with plasmids expressing proteins encoded by the S, M, and L segments. They then
- 15 transfected these cells with three plasmids encoding full-length anti-genomic cDNAs flanked by the T7 polymerase promoter and the hepatitis delta virus ribozyme. To increase the number of bunyavirus particles relative to the number of vaccinia virus particles, the authors used mosquito cells in which Bunyamwera but not Vaccinia virus replicates. This protocol can be used not
- 20 only to genetically engineer *Bunyaviridae*, but also generate reassortant viruses that cannot easily be obtained by coinfecting cells with different *Bunyaviridae* strains.

- To study bunyavirus promoter elements and the viral proteins that are required for transcription and replication, Dunn et al. (1995) cloned the CAT
- 25 gene in the negative-sense orientation between the 5' and 3' nontranslated regions of the Bunyamwera S RNA segment. Cells were transfected with constructs expressing the proteins encoded by the L and S segment and were then transfected with *in vitro* transcribed RNA, which resulted in CAT activity. The bunyavirus S segment encodes two proteins, N and NSs, in overlapping
- 30 reading frames. To determine whether both of these proteins are required for transcription and replication, constructs expressing only N or NSs were tested for CAT activity. N protein expression, together with L protein, resulted in CAT activity, whereas no CAT activity was detected with the NSs expression

construct. Thus, the L and N proteins are sufficient for transcription and replication of a bunyavirus-like RNA.

As with influenza virus, the terminal sequences of bunyavirus RNAs are complementary and highly conserved. It has therefore been assumed that these sequence elements define the bunyaviral promoter and are crucial for promoter activity. Deletion of five nucleotides at the 3' end of the viral RNA drastically reduces CAT expression (Dunn et al., 1995). In contrast, addition of two nucleotides at the 5' end, or of 11 or 35 nucleotides at the 3' end does not abolish CAT expression (Dunn et al., 1995). Therefore, like the influenza virus polymerase complex, the bunyavirus polymerase protein can apparently start transcription and/or replication internally.

The invention will be further described by the following examples.

Example 1

Materials and Methods

Cells and viruses. 293T human embryonic kidney cells and Madin-Darby canine kidney cells (MDCK) were maintained in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum and in modified Eagle's medium (MEM) containing 5% newborn calf serum, respectively. All cells were maintained at 37°C in 5% CO₂. Influenza viruses A/WSN/33 (H1N1) and A/PR/8/34 (H1N1) were propagated in 10-day-old eggs.

Construction of plasmids. To generate RNA polymerase I constructs, cloned cDNAs derived from A/WSN/33 or A/PR/8/34 viral RNA were introduced between the promoter and terminator sequences of RNA polymerase I. Briefly, the cloned cDNAs were amplified by PCR with primers containing *Bsm*BI sites, digested with *Bsm*BI, and cloned into the *Bsm*BI sites of the pHH21 vector which contains the human RNA polymerase I promoter and the mouse RNA polymerase I terminator, separated by *Bsm*BI sites (Figure 2). The PB2, PB1, PA, HA, NP, NA, M, and NS genes of the A/WSN/33 strain were PCR-amplified by use of the following plasmids: pSCWPB2, pGW-PB1, and pSCWPA (all obtained from Dr. Debi Nayak at the University of California Los Angeles), and pWH17, pWNP152, pT3WNA15 (Castrucci et al., 1992), pGT3WM, and pWNS1, respectively. The PB1 gene of influenza A/PR/8/34

virus was amplified by using pcDNA774 (PB1) (Perez et al., 1998) as a template. See Figure 6 for the sequences of the primers. To ensure that the genes were free of unwanted mutations, PCR-derived fragments were sequenced with an autosequencer (Applied Biosystem Inc., CA, USA) according to the protocol recommended by the manufacturer. The cDNAs encoding the HA, NP, NA, and M1 genes of A/WSN/33 virus were cloned as described (Huddleston et al., 1982) and subcloned into the eukaryotic expression vector pCAGGS/MCS (controlled by the chicken β -actin promoter) (Niwa et al., 1991), resulting in pEWSN-HA, pCAGGS-WSN-NPO-14, pCAGGS-WNA15, and pCAGGS-WSN-M1-2/1, respectively. The M2 and NS2 genes from the A/PR/8/34 virus were amplified by PCR and cloned into pCAGGS/MCS, yielding pEP24c and pCA-NS2. Finally, pcDNA774 (PB1), pcDNA762 (PB2), and pcDNA787 (PA) were used to express the PB2, PB1, and PA proteins under control of the cytomegalovirus promoter (Perez et al., 1998).

Generation of infectious influenza particles. 293T cells (1×10^6) were transfected with a maximum of 17 plasmids in different amounts with use of Trans ITTM LT-1 (Panvera, Madison, Wisconsin) according to the manufacturer's instructions. Briefly, DNA and transfection reagent were mixed (2 μ l Trans ITTM-LT-1 per μ g of DNA), incubated at room temperature for 45 minutes and added to the cells. Six hours later, the DNA-transfection reagent mixture was replaced by Opti-MEMTM (Gibco/BRL, Gaithersburg, Maryland) containing 0.3% bovine serum albumin and 0.01% fetal calf serum. At different times after transfection, viruses were harvested from the supernatant and titrated on MDCK cells. Since helper virus was not required by this procedure, the recovered transfectant viruses were analyzed without plaque purification.

Determination of the percentage of plasmid-transfected cells producing viruses. Twenty-four hours after transfection, 293T cells were dispersed with 0.02% EDTA into single cells. The cell suspension was then diluted 10-fold and transferred to confluent monolayers of MDCK cells in 24-well plates. Viruses were detected by the hemagglutination assay.

Immunostaining assay. Nine hours after infection with influenza virus, cells were washed twice with phosphate-buffered saline (PBS) and fixed with 3.7%

paraformaldehyde (in PBS) for 20 minutes at room temperature. Next, they were treated with 0.1 % Triton X-100 and processed as described by Neumann et al. (1997).

Results

Generation of infectious virus by plasmid-driven expression of viral RNA

5 segments, three polymerase subunits and NP protein. Although transfection of cells with a mixture of RNPs extracted from purified virions results in infectious influenza particles, this strategy is not likely to be efficient when used with eight different *in vitro* generated RNPs. To produce infectious influenza viruses entirely from cDNAs, eight viral RNPs were generated *in vivo*. Thus, plasmids were prepared that contain cDNAs
10 for the full-length viral RNAs of the A/WSN/33 virus, flanked by the human RNA polymerase I promoter and the mouse RNA polymerase I terminator. In principle, transfection of these eight plasmids into eukaryotic cells should result in the synthesis of all eight influenza vRNAs. The PB2, PB 1, PA and NP proteins, generated by cotransfection of protein expression plasmids, should then assemble the vRNAs into
15 functional vRNPs that are replicated and transcribed, ultimately forming infectious influenza viruses (Figure 3). 1×10^6 293T cells were transfected with protein expression plasmids (1 μ g of pcDNA762 (PB2), 1 μ g of pcDNA774 (PBI), 0.1 μ g of pcDNA787 (PA), and 1 μ g of pCAGGS-WSN-NPO/14) and 1 μ g of each of the following RNA polymerase I plasmids (pPolI-WSN-PB2, pPolI-WSN-PBI, pPolI-
20 WSN-PA, pPolI-WSN-HA, pPolI-WSN-NP, pPolI-WSN-NA, pPolI- WSN-M, and pPolI-WSN-NS). The decision to use a reduced amount of pcDNA787 (PA) was based on previous observations (Mena et al., 1996), and data on the optimal conditions for generation of virus-like particles (VLPs) (data not shown). Twenty-four hours after transfection of 293T cells, 7×10^3 pfu of virus per ml was found in the supernatant
25 (Experiment 1, Table 1), demonstrating for the first time the capacity of reverse genetics to produce influenza A virus entirely from plasmids.

Table 1. Plasmid sets used to produce influenza virus from cloned cDNA*

		Experiment							
RNA polymerase I plasmids for: [†]		1	2	3	4	5	6	7	8
	PB1	+	+	-	-	-	-	-	-
	PR8-PB1	-	-	+	+	+	+	+	+
	PB2	+	+	+	+	+	+	+	+
	PA	+	+	+	+	+	+	+	+
	HA	+	+	+	+	+	+	+	+
	NP	+	+	+	+	+	+	+	+
	NA	+	+	+	+	+	+	+	+
	M	+	+	+	+	+	+	+	+
	NS	+	+	+	+	+	+	+	+
Protein expression plasmids for:									
	PB1	+	+	+	+	-	+	+	+
	PB2	+	+	+	+	+	-	+	+
	PA	+	+	+	+	+	+	-	+
	NP	+	+	+	+	+	+	+	-
	HA	-	+	-	+	+	+	+	+
	NA	-	+	-	+	+	+	+	+
	M1	-	+	-	+	+	+	+	+
	M2	-	+	-	+	+	+	+	+
	NS2	-	+	-	+	+	+	+	+
Virus titer (pfu/ml)		7×10 ³	7×10 ³	1×10 ³	3×10 ⁴	0	0	0	0

* 293T cells were transfected with the indicated plasmids. Twenty-four (Experiments 1 and 2) or forty-eight hours (Experiments 3-8) later, the virus titer in the supernatant was determined in MDCK cells.

[†] Unless otherwise indicated, plasmids were constructed with cDNAs representing the RNAs of A/WSN/33 virus.

Efficiency of influenza virus production with coexpression of all viral structural proteins. Although expression of the viral NP and polymerase proteins is sufficient for
5 the plasmid-driven generation of influenza viruses, it was possible that the efficiency
could be improved. In previous studies, the expression of all influenza virus structural
proteins (PB2, PB1, PA, HA, NP, NA, M1, M2, and NS2) resulted in VLPs that
contained an artificial vRNA encoding a reporter chloramphenicol-acetyltransferase
gene (Mena et al., 1996). Thus, the availability of the entire complement of structural
10 proteins, instead of only those required for viral RNA replication and transcription,
might improve

the efficiency of virus production. To this end, 293T cells were transfected with optimal amounts of viral protein expression plasmids (as judged by VLP production; unpublished data): 1 µg of pcDNA762(PB2) and pcDNA774(PB1); 0.1 µg of pcDNA787(PA); 1 µg of pEWSN-HA, pCAGGS-WSN-NP0/14, and pCAGGS-WNA15; 2 µg of pCAGGS-WSN-M1-2/1; 0.3 µg of pCA-NS2; and 0.03 µg of pEP24c (for M2), together with 1 µg of each RNA polymerase I plasmid (Experiment 2, Table 1). A second set of cells was transfected with the same set of RNA polymerase I plasmids, with the exception of the PB1 gene, for which pPo1I-PR/8/34-PB1 was substituted in an effort to generate a reassortant virus, together with plasmids expressing only PA, PB1, PB2, and NP (Experiment 3, Table 1) or those expressing all the influenza structural proteins (Experiment 4, Table 1). Yields of WSN virus did not appreciably differ at 24 hours (Experiments 1 and 2, Table 1) or at 36 hours (data not shown) post-transfection. However, more than a 10-fold increase in yields of the virus with PR/8/34-PB1 was found when all the influenza viral structural proteins were provided (Experiments 3 and 4, Table 1). Negative controls, which lacked one of the plasmids for the expression of PA, PB1, PB2, of NP proteins, did not yield any virus (Experiments 5-8, Table 1). Thus, depending on the virus generated, expression of all influenza A virus structural proteins appreciably improved the efficiency of the reverse genetics method.

Next, the kinetics of virus production after transfection of cells was determined using the set of plasmids used to generate a virus with the A/PR/8/34-PB1 gene. In two of three experiments, virus was first detected at 24 hours after transfection. The titer measured at that time, $>10^3$ pfu/ml, had increased to $>10^6$ pfu/ml by 48 hours after transfection (Table 2). To estimate the percentage of plasmid-transfected cells that were producing viruses, 293T cells were treated with EDTA (0.02%) at 24 hours after transfection to disperse the cells, and then performed limiting dilution studies. In this experiment, no free virus was found in the culture supernatant at this time point. The results indicated that 1 in $10^{3.3}$ cells was generating infectious virus particles.

Table 2. Kinetics of virus production after plasmid transfection into 293T cells*

	Hours after plasmid transfection	Virus titers in culture supernatant (pfu/ml)		
		Experiment		
		1	2	3
5	6	0	ND	ND
	12	0	ND	0
	18	0	ND	0
	24	0	2×10^3	6×10^3
	30	ND	5×10^4	9×10^4
10	36	6×10^2	$> 1 \times 10^5$	7×10^5
	42	ND	$> 1 \times 10^6$	5×10^6
	48	8×10^4	$> 1 \times 10^6$	1×10^7

* 293T cells were transfected with eight RNA polymerase I plasmids encoding A/WSN/33 virus genes with the exception of PB1 gene, which is derived from A/PR/8/34 virus, and nine protein expression plasmids as described in the text. At different time points, we titrated virus in the culture supernatant in MDCK cells. ND = not done.

Recovery of influenza virus containing the FLAG epitope in the NA protein. To verify that the new reverse genetics system allowed the introduction of mutations into the genome of influenza A viruses, a virus containing a FLAG epitope (Castrucci et al., 1992) in the NA protein was generated. 293T cells were transfected with an RNA polymerase I plasmid (pPolI-WSN-NA/FL79) that contained a cDNA encoding both the NA protein and a FLAG epitope at the bottom of the protein's head, together with the required RNA polymerase I and protein expression plasmids. To confirm that the recovered virus (PR8-WSN-FL79) did in fact express the NA-FLAG protein, immunostaining assays of cells infected with PR8-WSN-FL79 or A/WSN/33 wild-type virus was performed. A monoclonal antibody to the FLAG epitope detected cells infected with PR8-WSN-FL79, but not those infected with wild-type virus (Figure 4). Recovery of the PR8-WSN-FL79 virus was as efficient as that for the untagged wild-type virus (data not shown). These results indicate that the new reverse genetics system allows one to introduce mutations into the influenza A virus genome.

Generation of infectious influenza virus containing mutations in the PA gene. To produce viruses possessing mutations in the PA gene, two silent

mutations were introduced creating new recognition sequences for restriction endonucleases (*Bsp*120I at position 846 and *Pvu*II at position 1284 of the mRNA). Previously, it was not possible to modify this gene by reverse genetics, because of the lack of a reliable selection system. Transfectant viruses, PA-
5 T846C and PA-A1284 were recovered. The recovered transfectant viruses were biologically cloned by two consecutive limiting dilutions. To verify that the recovered viruses were indeed transfectants with mutations in the PA gene, cDNA for the PA gene was obtained by reverse transcriptase-PCR. As shown in Figure 5, PA-T846C and PA-A1284C viruses had the expected mutations within
10 the PA gene, as demonstrated by the presence of the newly introduced restriction sites. PCR of the same viral samples and primers without the reverse transcription step failed to produce any products (data not shown), indicating that the PA cDNA was indeed originated from vRNA instead of the plasmid used to generate the viruses. These results illustrate how viruses with mutated genes can
15 be produced and recovered without the use of helper viruses.

Discussion

The reverse genetics systems described herein allows one to efficiently produce influenza A viruses entirely from cloned cDNAs. Bridgen and Elliott (1996) also used reverse genetics to generate a Bunyamwera virus (*Bunyaviridae*
20 family), but it contains only three segments of negative-sense RNA, and the efficiency of its production was low, 10^2 pfu/ 10^7 cells. Although the virus yields differed among the experiments, consistently $> 10^3$ pfu/ 10^6 cells was observed for influenza virus, which contains eight segments. There are several explanations for the high efficiency of the reverse genetics system described
25 hereinabove. Instead of producing RNPs *in vitro* (Luytjes et al., 1989), RNPs were generated *in vivo* through intracellular synthesis of vRNAs using RNA polymerase I and through plasmid-driven expression of the viral polymerase proteins and NP. Also, the use of 293T cells, which are readily transfected with plasmids (Goto et al., 1997), ensured that a large population of cells received all
30 of the plasmids needed for virus production. In addition, the large number of transcripts produced by RNA polymerase I, which is among the most abundantly expressed enzymes in growing cells, likely contributed to the overall efficiency of the system. These features led to a correspondingly abundant number of

vRNA transcripts and adequate amounts of viral protein for encapsidation of vRNA, formation of RNPs in the nucleus, and export of these complexes to the cell membrane, where new viruses are assembled and released.

Previously established reverse genetics systems (Enami et al., 1990; 5 Neumann et al., 1994; Luytjes et al., 1989; Pleschka et al., 1996) require helper-virus infection and therefore selection methods that permit a small number of transfectants to be retrieved from a vast number of helper viruses. Such strategies have been employed to generate influenza viruses that possess one of the following cDNA-derived genes: PB2 (Subbarao et al., 1993), HA (Enami et 10 al., 1991; Horimoto et al., 1994), NP (Li et al., 1995), NA (Enami et al., 1990), M (Castrucci et al., 1995; Yasuda et al., 1994), and NS (Enami et al., 1991). Most of the selection methods, except for those applicable to the HA and NA genes, rely on growth temperature, host range restriction, or drug sensitivity, thus limiting the utility of reverse genetics for functional analysis of the gene 15 products. Even with the HA and NA genes, for which reliable antibody-driven selection systems are available, it is difficult to produce viruses with prominent growth defects. In contrast, the reverse genetics system described herein does not require helper virus and permits one to generate transfectants with mutations in any gene segment or with severe growth defects. This advantage is 20 demonstrated in Figure 5, which the recovery of transfectant viruses with a mutated PA gene. Having the technology to introduce any viable mutation into the influenza A virus genome will enable investigators to address a number of long-standing issues, such as the nature of regulatory sequences in nontranslated regions of the viral genome, structure-function relationships of viral proteins, 25 and the molecular basis of host-range restriction and viral pathogenicity.

Although inactivated influenza vaccines are available, their efficacy is suboptimal due partly to their limited ability to elicit local IgA and cytotoxic T cell responses. Clinical trials of cold-adapted live influenza vaccines now underway suggest that such vaccines are optimally attenuated, so that they will 30 not cause influenza symptoms, but will still induce protective immunity (reviewed in Keitel & Piedra, 1998). However, preliminary results indicate that these live virus vaccines will not be significantly more effective than the best inactivated vaccine (reviewed in Keitel. & Piedra, 1998), leaving room for

further improvement. One possibility would be to modify a cold-adapted vaccine with the reverse genetics system described above. Alternatively, one could start from scratch by using reverse genetics to produce a “master” influenza A strain with multiple attenuating mutations in the genes that encode internal proteins. The most intriguing application of the reverse genetics system described herein may lie in the rapid production of attenuated live-virus vaccines in cases of suspected pandemics involving new HA or NA subtypes of influenza virus.

This new reverse genetics system will likely enhance the use of influenza viruses as vaccine vectors. The viruses can be engineered to express foreign proteins or immunogenic epitopes in addition to the influenza viral proteins. One could, for example, generate viruses with foreign proteins as a ninth segment (Enami et al., 1991) and use them as live vaccines. Not only do influenza viruses stimulate strong cell-mediated and humoral immune responses, but they also afford a wide array of virion surface HA and NA proteins (e.g., 15 HA and 9 NA subtypes and their epidemic variants), allowing repeated immunization of the same target population.

Influenza VLPs possessing an artificial vRNA encoding a reporter gene have been produced by expressing viral structural proteins and vRNA with the vaccinia-T7 polymerase system (Mena et al., 1996). Using reverse genetics, one can now generate VLPs containing vRNAs that encode proteins required for vRNA transcription and replication (i.e., PA, PB1, PB2, and NP), as well as vRNAs encoding proteins of interest. Such VLPs could be useful gene delivery vehicles. Importantly, their lack of genes encoding viral structural proteins would ensure that infectious viruses will not be produced after VLP-gene therapy. Since the influenza virus genome is not integrated into host chromosome, the VLP system would be suitable for gene therapy in situations requiring only short-term transduction of cells (e.g., for cancer treatment). In contrast to adenovirus vectors (Kovesdi et al., 1997), influenza VLPs could contain both HA and NA variants, allowing repeated treatment of target populations.

The family *Orthomyxoviridae* comprises influenza A, B, and C viruses, as well as the recently classified Thogotovirus. The strategy for generating

infectious influenza A viruses entirely from cloned cDNAs described herein would apply to any orthomyxovirus, and perhaps to other segmented negative-sense RNA viruses as well (e.g., *Bunyaviridae*, *Arenaviridae*). The ability to manipulate the viral genome without technical limitations has profound
5 implications for the study of viral life cycles and their regulation, the function of viral proteins and the molecular mechanisms of viral pathogenicity.

Example 2

Expression of the influenza virus proteins PB2, PB1, PA, and NP leads to
10 replication and transcription of an artificial viral RNA. To generate influenza VLPs, the RNA polymerase I system for the intracellular synthesis of influenza viral RNAs *in vivo* was employed (Figure 7). In this system, a cDNA encoding a reporter gene in antisense orientation is flanked by the 5' and 3' noncoding regions of an influenza viral RNA. This cassette is inserted between an RNA
15 polymerase I promoter and terminator. Transfection of such constructs into eukaryotic cells leads to transcription of the reporter gene by cellular RNA polymerase I, thereby generating influenza virus-like RNAs (Neumann et al., 1994). Upon influenza virus infection, the artificial vRNAs are replicated and transcribed by the viral polymerase complex, resulting in the expression of the
20 reporter gene.

To determine whether expression of the PB2, PB1, PA, and NP proteins leads to expression of the reporter gene encoded by the RNA polymerase I-derived transcript, plasmids (1 µg each) expressing the NP protein of A/WSN/33 (H1N1) virus under control of the chicken β -actin promoter (pCAGGS-WSN-
25 NP0/14), the polymerase proteins of A/PR/8/34 virus under control of the cytomegalovirus promoter [pcDNA762(PB2), pcDNA774(PB1), and pcDNA787(PA)], and an RNA polymerase I reporter gene construct (pPolI-GFP) were transfected into human embryonic kidney (293T) cells. Forty eight hours later, 30%-40% of the cells were expressing GFP (Figure 9). In contrast, GFP
30 expression could not be detected in transfected cells lacking the polymerase or NP proteins. These results indicated that NP and the three influenza viral polymerase proteins had formed a functional complex that replicated and transcribed the RNA polymerase I-derived GFP vRNA.

Optimal vRNA transcription and replication. To determine the amounts of plasmid DNA required for optimal reporter GFP expression, we modulated the expression of the polymerase proteins and NP. Previous studies had indicated that large amounts of PA reduce the extent of reporter gene expression in transcription/replication systems (Mena et al., 1996). Therefore, in a stepwise manner, the expression of PA from the plasmid was reduced, identifying 0.1 µg of pcDNA787(PA) as the template amount yielding the strongest expression of GFP. With NP, the major structural component of RNP complexes, high amounts of protein expression plasmid may be required. However, higher amounts of the plasmid did not appreciably affect the number of GFP-positive 293T cells. In addition, various amounts of the PB2 and PB1 protein expression plasmids (ranging from 1.0 to 0.03 µg) did not affect the GFP expression in 293T cells. Hence, in all subsequent experiments, 0.1 µg of pcDNA787(PA), and 1.0 µg of pcDNA774(PB1), pcDNA762(PB2), and pCAGGS-WSN-NP0/14, was used.

Formation of influenza VLPs from cloned cDNAs. Previous studies with the vaccinia virus T7 RNA polymerase system showed that the formation of influenza VLPs requires nine influenza virus proteins: PB2, PB1, PA, HA, NA, NP, M1, M2, and NS2 (Mena et al., 1996). The NS1 protein, by contrast, is dispensable for particle formation (Mena et al., 1996). To establish an efficient plasmid-driven system for VLP generation, cDNAs were generated that encoded the HA, NA, M1, M2, and NS2 genes. The cDNAs were cloned into the eukaryotic expression vector pCAGGS/MCS (controlled by the chicken β-actin promoter), resulting in pEWSN-HA, pCAGGS-WNA15, pCAGGS-WSN-M1-2/1, pEP24c, and pCA-NS2, respectively. Expression of each protein was confirmed by Western blot analysis.

To generate VLPs, 10⁶ 293T cells were transfected with 1.0 µg of each protein expression plasmids (with the exception of pcDNA787(PA), for which 0.1 µg was employed), and with 1 µg of the reporter gene construct pPoll-GFP. Culture supernatants were harvested 48 hours after transfection and mixed with A/WSN/33 virus to provide the influenza virus proteins required for replication and transcription of GFP vRNA. The mixture was then inoculated into MDCK cells. Ten hours after incubation, GFP-positive MDCK cells were detected,

corresponding to 450 particles/ml of supernatant (Table 3). Thus, plasmid-driven expression of all influenza viral structural proteins resulted in the formation of infectious influenza VLPs containing GFP vRNA. Moreover, GFP vRNA was delivered to MDCK cells.

5 Optimal assembly of influenza virus. VLP formation was also studied in cells expressing different amounts of the RNA polymerase I reporter gene construct, as well as HA, NA, M1, M2, and NS2 plasmid DNAs. In experiments with pPolI-GFP, 1.0 µg of the plasmid DNA was highly efficient in generating VLPs, whereas the efficiency was significantly reduced for 2.0 µg or 3.0 µg.

10 Because the NS2 and M2 proteins are expressed in low amounts late in infection, it was likely that relatively small amounts of the expression plasmids would be needed for optimal VLP formation. Reduction of the M2 expression construct from 1.0 µg to 0.3 µg resulted in a more than tenfold increase in the number of GFP-positive MDCK cells (Table 3). Further reduction of plasmid to 0.03 µg
15 did not increase the number of VLPs. For NS2, lower amounts of plasmid tested (0.1 µg) were associated with less efficient formation of VLPs (Table 3).

 The M1 protein is the major structural component of the virion. Thus, high levels of M1 expression are likely required for efficient formation of VLPs. This prediction was tested in experiments comparing VLP formation in cells
20 transfected with 1.0 µg or 2.0 µg of M1 plasmid DNA. As shown in Table 3, higher amounts of plasmid resulted in a more than tenfold increase in the number of GFP-positive MDCK cells. Comparison of two different amounts (1 µg vs. 2 µg) of plasmids expressing the HA and NA proteins did not reveal any appreciable differences in VLP formation, leading to selection of 1 µg of each
25 plasmid (pEWSN-HA, pCAGGS-WNA15) for use in subsequent experiments. Overall, these studies resulted in a >100-fold increase in the efficiency of VLP formation, ultimately leading to the production of more than 10⁴ infectious influenza virus particles per ml of supernatant (Figure 10).

Table 3. Optimal amounts of plasmid DNA for the formation of infectious VLPs.*

	Amount (µg) of plasmid DNA expressing:										Relative efficiency of VLP formation†
	PB2	PB1	PA	HA	NP	NA	M1	M2	NS2	GFP vRNA	
5	1.0	1.0	0.1	1.0	1.0	1.0	1.0	1.0	1.0	1.0	1
	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.1	1.0	1.0	28
	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.03	1.0	1.0	17
10	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.1	1.0	1.0	28
	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.1	0.3	1.0	24
	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.1	0.1	1.0	11
20	1.0	1.0	0.1	1.0	1.0	1.0	1.0	0.1	1.0	1.0	28
	1.0	1.0	0.1	1.0	1.0	1.0	2.0	0.1	1.0	1.0	220

83

15 *293T cells were transfected with expression plasmids for all nine influenza virus structural proteins and with the RNA polymerase I-GFP gene plasmid. Forty-eight hours after transfection, VLP-containing supernatants were collected, mixed with A/WSN/33 helper virus, and inoculated into MDCK cells. The cells were fixed 10 h after infection and GFP expression was determined with a fluorescence microscope. Only the amounts of the M1, M2, and NS2 plasmids were varied (bold letter) to determine their optimal amounts for GFP expression in MDCK cells.

20 † The relative efficiency of VLP formation was determined by counting the number of GFP-positive cells in five microscopic fields. The sample containing 1 µg of each plasmid (which yielded 450 infectious VLP/ml of supernatant) was chosen as the reference (value of 1).

Authenticity of VLPs produced entirely from plasmids. To verify that VLPs initiate infection in the same manner as authentic influenza viruses, VLPs were neutralized with antibody to the WSN HA. VLP-containing supernatants
5 derived from plasmid-transfected 293T cells were incubated with a pool of anti-WSN HA monoclonal antibodies or with a monoclonal antibody to the G protein of vesicular stomatitis virus (VSV) (negative control) for 1 hour at room temperature. A/PR/8/34 helper virus, which is not neutralized by the pool of anti-WSN HA monoclonal antibodies, was added to the mixture and inoculated into
10 MDCK cells. Only the anti-WSN-HA-specific monoclonal antibody neutralized the VLPs, indicating that the HA mediates the attachment and entry of VLPs into cells.

Next, the minimal set of proteins required for the formation of VLPs was identified. Other have established that the three influenza virus polymerases and
15 the NP are essential for the replication and transcription of vRNA (Honda et al., 1988). Therefore, each of these four proteins was included, but HA, NA, M1, M2, or NS2 was consecutively omitted. Exclusion of any of these plasmids did not affect the replication/transcription of GFP vRNA in transfected 293T cells. Supernatants derived from transfected 293T cells that lacked the HA, NA, M1,
20 or NS2 protein did not promote GFP expression in infected MDCK cells, indicating the absence of infectious VLPs. Infectious VLPs were detected with omission of M2 but the number was low (> 500 fold reduction compared to the full set of structural proteins). Thus, all influenza virus structural proteins are required for the efficient formation of infectious VLPs, in accord with data from
25 studies of the vaccinia-virus system (Mena et al., 1996).

VSV glycoprotein can replace the HA and NA proteins in the production of VLPs. The influenza virus HA and NA proteins were replaced with the VSV G protein, which functions in receptor binding and fusion. In 293T cells transfected with pPoll-GFP; optimal amounts of the PB2, PB1, PA, NP, M1,
30 M2, and NS2 expression constructs; and 1 µg of the VSV-G construct (pCAGGS-VSV-G), substitution of the VSV-G protein for influenza virus glycoproteins did not adversely affect VLP formation. To the contrary, higher numbers of GFP-positive cells were reproducibly found when VSV-G, rather

than the HA and NA, served as the viral glycoprotein. Thus, the VSV G protein can be efficiently incorporated into influenza virions and can function as well as the HA and NA in virus release and entry.

An efficient system for generating infectious influenza virus particles would be an asset in research with this virus and potentially in the production of vaccines and vectors for gene therapy. In contrast to the extant vaccinia virus system, the VLP production strategy described here is highly efficient, both in the initial transfection of cells and in the yield of VLPs ($>10^4$ infectious particles/ml of supernatant). Moreover, it is driven entirely by plasmids expressing influenza virus proteins (i.e., in the absence of any other viral proteins), which greatly simplifies the interpretation of results. Another major advantage is the capability to study the effects of lethal mutations in virion formation, packaging of RNP complexes, budding of virus replication, and binding and fusion processes. In addition, it is likely that the system described hereinabove would operate equally well with other viruses, e.g., paramyxoviruses and rhabdoviruses.

Influenza virus HA and NA proteins can be functionally replaced by the VSV glycoprotein G. Previously, it had been reported that influenza viruses failed to incorporate VSV G protein when provided by recombinant SV40 virus (Naim et al., 1993). The results described herein suggest that neither the HA nor the NA is essential for the formation of VLPs, although it cannot be ruled out that these glycoproteins play a role in interactions with other viral proteins, thus affecting the structure of virions, as suggested by the elongated shapes of viruses expressing tail-less HAs, NAs, or both (Garcia-Sastre et al., 1995; Jin et al., 1994; Jin et al., 1997; Mitnaul et al., 1996).

The plasmid-based system described hereinabove may be particularly useful for therapeutic gene delivery. VLPs can be prepared that contain the vRNA encoding the proteins required for transcription and replication (i.e., the NP and the polymerases), as well as a vRNA encoding the protein of interest. These particles are infectious and can deliver a designated gene into target cells, where it would replicate and be transcribed. Because these particles do not contain a complete complement of viral genes, they can not produce infectious progeny viruses. This feature, together with the lack of integration of the viral

genome into host chromosomes, would ensure the biological safety of gene delivery in human and nonhuman subjects. Finally, the availability of 15 HA and 9 NA subtypes and their variants would allow the repeated administration of VLPs, thereby overcoming immunoresistance to vector-generated proteins, one of the major obstacles faced with repeated use of other viral vectors, such as adenoviruses. A further benefit of the plasmid-driven system would be realized in situations requiring only short-term expression of foreign proteins, as in cancer treatment.

Example 3

By using the Cre-loxP system, one can generate packaging cell lines for the production of replication-defective viruses. For example, a protein expression vector is prepared that contains a transcription stop cassette (e.g., pBS302 of Life Technologies, Bethesda, Maryland; and Sauer et al., 1993; Lasko et al., 1992; Pichel et al., 1993; Bolivar et al., 1977; Stuhl et al., 1981; Stuhl, 1985; Fiers et al., 1978), flanked by two *loxP* sites, and one of the viral genes. Transcription, initiated at the promoter sequence, is blocked at the transcription stop sites. Thus, the viral gene is not transcribed and translated. A cell that is stably transfected with such a vector is infected with an influenza virus that lacks the vRNA encoding the gene cloned into the *loxP* system. This virus also contains an additional vRNA encoding the Cre protein. This virus is not viable in normal cells, because it lacks one of its vRNAs. However, in the packaging cell line, the Cre protein which is expressed from the vRNA results in recombination at the *loxP* site, resulting in the deletion of the transcription stop site. Thus, the respective viral gene(s) is now transcribed and expressed, allowing the virus to amplify in these cells (Figure 11).

In addition, packaging cell lines are prepared that express the late viral proteins (i.e., HA, NA, M1, M2, and NS2) controlled by the *loxP* system (Figure 12). The HA and NA can be replaced by other viral receptor-binding and fusion proteins (e.g., Ebola GP, Marburg GP, Bunyaviridae glycoproteins GP1 and GP2, the G and/or F proteins of rhabdovirus and paramyxovirus, thogotovirus

glycoprotein, and the glycoproteins of positive-strand RNA viruses). Virus-like particles are generated which contain the vRNAs encoding the proteins required for replication/transcription (i.e., the polymerase and NP proteins), a vRNA encoding the gene of interest, and a vRNA encoding Cre. These vRNAs
 5 are packaged into virus-like particles in the packaging cell lines.

These virus-like particles can be used for vaccine and gene therapy purposes because (i) they do not contain the full complement of viral genes and thus no infectious progeny particles can be formed, meeting the stringent safety
 10 concerns; (ii) they will likely express the foreign protein at high levels; (iii) they do not express the viral glycoproteins (HA, NA) that are the major antigens; thus, the host immune response against the viral proteins should be limited.

15 References

- Albo, C., Martin, J., and Portela, A. J. Virol., 70, 9013-9017 (1996).
 Baron, M. D. & Barrett, T. J. Virol., 71, 1265-1271 (1997).
 Bolivar et al. Gene, 2, 95 (1977).
 Bridgen, A. & Elliott, R. M. Proc. Natl. Acad. Sci. U.S.A., 93, 15400-
 20 15404 (1996).
 Castrucci, M. R. & Kawaoka, Y. J. Virol., 69, 2725-2728 (1995).
 Castrucci, M. R., Bilsel, P. & Kawaoka, Y. J. Virol., 66, 4647-4653
 (1992).
 Collins, P. L., Hill, M. G., Camargo, E., Grosfeld, H., Chanock, R. M. &
 25 Murphy, B. R. Proc. Natl. Acad. Sci. U.S.A., 92, 11563-11567 (1995).
 Cozelmann, K. K. & Schnell, M. J. Virol., 68, 713-719 (1994).
 Dunn, E.F., Pritlove, D.C., Jin, H., and Elliott, R.M. Virology, 211, 133-
 143 (1995).
 Elliott, R.M. Mol. Med., 3, 572-577 (1997).
 30 Enami, M., Sharma, G., Benham, C. & Palese, P. Virology, 185, 291-
 298 (1991).
 Enami, M. & Palese, P. J. Virol., 65, 2711-2713 (1991).

- Enami, M., Luytjes, W., Krystal, M. & Palese, P. Proc. Natl. Acad. Sci. U.S.A., **87**, 3802-3805 (1990).
- Fiers et al. Nature, **273**, 113 (1978).
- Garcia-Sastre, A. And P. Palese. Virus Res., **37**, 37-47 (1995).
- 5 Garcin, D., Pelet, T., Calain, P., Roux, L., Curran, J. & Kolakofsky, D. EMBO J., **14**, 6087-6094 (1995).
- Goto, H., Bethell, R. C. & Kawaoka, Y. Virology, **238**, 265-272 (1997).
- Hagen, M., Chung, T.D.Y., Butcher, J.A., and Krystal, M. J. Virol., **68**, 1509-1515 (1994).
- 10 He, B., Paterson, R. G., Ward, C. D. & Lamb, R. A. Virology, **237**, 249-260 (1997).
- Hoffman, M. A. & Banerjee, A. K. J. Virol., **71**, 4272-4277 (1997).
- Honda, A., K. Ueda, K. Nagata, and A. Ishihama., J. Biochem. (Tokyo), **104**, 1021-1026 (1988).
- 15 Horimoto, T. & Kawaoka, Y. J. Virol., **68**, 3120-3128 (1994).
- Huddleston, J. A. & Brownless, G. G. Nucl. Acids Res., **10**, 1029-1037 (1982).
- Jin, H., G.P. Leser and R.A. Lamb. EMBO J., **13**, 5504-5515 (1994).
- Jin, H., G.P. Leser, J. Zhang, and R.A. Lamb. EMBO J., **16**, 1236-1247
- 20 (1997).
- Kato, A., Sakai, Y., Shioda, T., Kondo, T., Nakanishi, M. & Nagai, Y. Genes Cells, **1**, 569-579 (1996).
- Keitel, W. A. & Piedra, P. A. in Textbook of Influenza, eds. Nickolson, K. G., Webster, R. G., and Hay, A. (Blackwell, Oxford), pp. 373-390 (1998).
- 25 Kovesdi, I., Brough, D. E., Bruder, J. T. & Wickham, T. J. Curr. Opin. Biotechnol., **8**, 583-589 (1997).
- Lasko et al. Proc. Natl. Acad. Sci. USA, **89**, 6232 (1992).
- Lawson, N. D., Stillman, E. A., Whitt, M. A. & Rose, J. K. Proc. Natl. Acad. Sci. U.S.A., **92**, 4477-4481 (1995).
- 30 Leahy, M.B., Dessens, J.T., and Nuttall, P.A. J. Virol., **71**, 8347-8351 (1997).
- Leahy, M.B., Dessens, J.T., and Nuttall, P.A. J. Virol., **71**, 8352-8356 (1997) .

- Leahy, M.B., Dessens, J.T., Pritlove, D.C., and Nuttall, P.A. J. Virol., **72**, 2305-2309 (1998).
- Li, S., Xu, M. & Coelingh, K. Virus Res., **37**, 153-161 (1995).
- Luytjes, W., Krystal, M., Enami, M., Parvin, J. D. & Palese, P. Cell, **59**,
5 1107-1113 (1989).
- Mena, I., Vivo, A., Pérez, E. & Portela, A. J. Virol., **70**, 5016-5024
(1996).
- Naim, H.Y. and M.G. Roth. J. Virol., **67**, 4831-4841 (1993).
- Neumann, G., Castrucci, M. R. & Kawaoka, Y. J. Virol., **71**, 9690-9700
10 (1997).
- Neumann, G., Zobel, A. & Hobom, G. Virology, **202**, 477-479 (1994).
- Niwa, H., Yamamura, K. & Miyazaki, J. Gene, **108**, 193-200 (1991).
- Palese, P., Zheng, H., Engelhardt, O. G., Pleschka, S. & Garcia-Sastre, A.
Proc. Natl. Acad. Sci. U.S.A., **93**, 11354-11358 (1996).
- 15 Perez, D. R. & Donis, R. O. Virology, **249**, 52-61 (1998).
- Pichel et al. Oncogene, **8**, 3333 (1993).
- Pleschka, S., Jaskunas, S. R., Engelhardt, O. G., Zürcher, T., Palese, P. &
García-Sastre, A. J. Virol., **70**, 4188-4192 (1996).
- Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dotsch,
20 C., Christiansen, G. & Gillet, M. A. EMBO J., **14**, 5773-5784 (1995).
- Schnell, M.J., Mebatsion, T., and Conzelmann, K.K. EMBO J., **13**,
4195-4203 (1994).
- Struhl, K. NAR, **13**, 8587 (1985).
- Struhl, K. et al. J. Mol. Biol., **152**, 553 (1985).
- 25 Subbarao, E. K., Kawaoka, Y. & Murphy, B. R. J. Virol., **67**, 7223-7228
(1993).
- Weber, F., Haller, O., and Kochs, G. J. Virol., **70**, 8361-8367 (1996).
- Weber, F., Haller, O., and Kochs, G. Arch. Virol., **142**, 1029-1033
(1997).
- 30 Whelan, S. P., Ball, L. A., Barr, J. N. & Wertz, G. T. Proc. Natl. Acad.
Sci. U.S.A., **92**, 8388-8392 (1995).
- Yasuda, J., Bucher, D. J. & Ishihama, A. J. Virol., **68**, 8141-8146 (1994).

While in the foregoing specification this invention has been described in relation to certain preferred embodiments thereof, and many details have been set forth for purposes of illustration, it will be apparent to those skilled in the art that the invention is susceptible to additional embodiments and that certain of the details
5 described herein may be varied considerably without departing from the basic principles of the invention.

SEQUENCE LISTING

<110> Wisconsin Alumni Research Foundation
 <120> Recombinant influenza viruses for vaccines and gene therapy
 <130> 93040-1
 <140> 2,365,526
 <141> 2000-04-05
 <150> 60/127,912
 <151> 1999-04-06
 <150> 60/132,839
 <151> 1999-05-06
 <160> 30
 <170> PatentIn Ver. 2.1
 <210> 1
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:plasmid sequence
 <400> 1
 gggttattgg agacggtacc gtctcctccc ccc 33
 <210> 2
 <211> 33
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:plasmid sequence
 <400> 2
 cccaataacc tctgccatgg cagaggaggg ggg 33
 <210> 3
 <211> 18
 <212> DNA
 <213> Artificial Sequence
 <220>
 <223> Description of Artificial Sequence:end of PCR product
 <220>
 <221> unsure
 <222> (7)

<223> can be any nucleotide

<400> 3

cgtctcntat tagtagaa

18

<210> 4

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:end of PCR
product

<220>

<221> unsure

<222> (7)

<223> can be any nucleotide

<400> 4

gcagagnata atcatctt

18

<210> 5

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:end of PCR
product

<220>

<221> unsure

<222> (11)

<223> can be any nucleotide

<400> 5

ttttgctccc ngagacg

17

<210> 6

<211> 17

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:end of PCR
product

<220>

<221> unsure

<222> (11)

<223> can be any nucleotide

<400> 6

aaaacgaggg nctctgc

17

<210> 7
 <211> 11
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of
 restriction enzyme digestion product

<400> 7
 tattagtaga a 11

<210> 8
 <211> 10
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of
 restriction enzyme digestion product

<400> 8
 aaaacgaggg 10

<210> 9
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of ligation
 reaction product

<400> 9
 gggttattag tagaa 15

<210> 10
 <211> 15
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of ligation
 reaction product

<400> 10
 cccaataatc atctt 15

<210> 11
 <211> 13
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of ligation
 reaction product

<400> 11
 ttttgctccc ccc 13

<210> 12
 <211> 13
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:end of ligation
 reaction product

<400> 12
 aaaacgaggg ggg 13

<210> 13
 <211> 28
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:plasmid
 sequence

<220>
 <221> misc_feature
 <222> (1)..(5)
 <223> 5' RNA polymerase I terminator

<220>
 <221> misc_feature
 <222> (6)..(28)
 <223> NP-NTR (5' end of vRNA)

<400> 13
 ttattagtag aaacaagggt atttttct 28

<210> 14
 <211> 43
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:plasmid
 sequence

<220>
 <221> misc_feature
 <222> (1)..(39)
 <223> NP-NTP (3' end of vRNA)

<220>
 <221> misc_feature
 <222> (40)..(43)
 <223> 3' end RNA polymerase I terminator

<400> 14
 gatgtcactc agtgagtgat tatctaccct gtttctactc ccc 43

<210> 15
 <211> 80
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(80)
 <223> Influenza virus sequence

<400> 15
 cacacacgtc tcgtattagt agaaacaagg tcgtttttaa actattcgac actaattgat 60
 ggccatccga attcttttgg 80

<210> 16
 <211> 67
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(67)
 <223> Influenza virus sequence

<400> 16
 cacacacgtc tccgggagcg aaagcaggtc aattatattc aatatggaaa gaataaaaga 60
 actaagg 67

<210> 17
 <211> 89
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature

<222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(89)
 <223> Influenza virus sequence

<400> 17
 cacacacgtc tcgtattagt agaaacaagg cattttttca tgaaggacaa gctaaattca 60
 ctatttttgc cgtctgagct cttcaatgg 89

<210> 18
 <211> 67
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(67)
 <223> Influenza virus sequence

<400> 18
 cacacacgtc tccgggagcg aaagcaggca aaccatttga atggatgtca atccgacttt 60
 actttttc 67

<210> 19
 <211> 103
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(103)
 <223> Influenza virus sequence

<400> 19
 ccaaccgctc tcctattagt agaaacaagg tacttttttg gacagtatgg atagcaaata 60
 gtagcattgc cacaactatc tcaatgcatg tgtgaggaag gag 103

<210> 20

<211> 67
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(67)
 <223> Influenza virus sequence

<400> 20
 ccaacccgtc tccgggagcg aaagcaggta ctgattcaaa atggaagatt ttgtgcgaca 60
 atgcttc 67

<210> 21
 <211> 40
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(40)
 <223> Influenza virus sequence

<400> 21
 cacacacgtc tcctattagt agaaacaagg gtgtttttcc 40

<210> 22
 <211> 45
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(45)

<223> Influenza virus sequence

<400> 22

cacacacgtc tccgggagca aaagcagggg aaaataaaaa caacc

45

<210> 23

<211> 47

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<220>

<221> misc_feature

<222> (7)..(12)

<223> BsmBI recognition sequence

<220>

<221> misc_feature

<222> (18)..(47)

<223> Influenza virus sequence

<400> 23

cacacacgtc tcctattagt agaaacaagg gtatTTTTtct ttaattg

47

<210> 24

<211> 42

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<220>

<221> misc_feature

<222> (7)..(12)

<223> BsmBI recognition sequence

<220>

<221> misc_feature

<222> (17)..(42)

<223> Influenza virus sequence

<400> 24

cacacacgtc tccgggagca aaagcagggg agataatcac tc

42

<210> 25

<211> 46

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR primer

<220>

<221> misc_feature

<222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(46)
 <223> Influenza virus sequence

<400> 25
 cacacacgtc tcctattagt agaaacaagg agttttttga acaaac

46

<210> 26
 <211> 48
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(48)
 <223> Influenza virus sequence

<400> 26
 cacacacgtc tccgggagcg aaagcaggag tttaaataaa tccaaacc

48

<210> 27
 <211> 47
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(47)
 <223> Influenza virus sequence

<400> 27
 cacacacgtc tcctattagt agaaacaagg tagtttttta ctccagg

47

<210> 28
 <211> 41
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(41)
 <223> Influenza virus sequence

<400> 28
 cacacacgtc tccgggagca aaagcaggta gatattgaaa g 41

<210> 29
 <211> 53
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (18)..(53)
 <223> Influenza virus sequence

<400> 29
 cacacacgtc tcctattagt agaaacaagg gtgttttttta ttattaaata agc 53

<210> 30
 <211> 46
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence:PCR primer

<220>
 <221> misc_feature
 <222> (7)..(12)
 <223> BsmBI recognition sequence

<220>
 <221> misc_feature
 <222> (17)..(46)
 <223> Influenza virus sequence

<400> 30
 cacacacgtc tccgggagca aaagcagggt gacaaagaca taatgg 46

WHAT IS CLAIMED IS:

1. A method to prepare a gene delivery vehicle, comprising:

transfecting cells with a plurality of orthomyxovirus vectors, which are sufficient to produce infectious influenza viruses in a host cell in the absence of helper virus, said vectors comprising:

a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PA cDNA linked to a RNA polymerase I transcription termination sequence,

a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PB1 cDNA linked to a RNA polymerase I transcription termination sequence,

a vector comprising a RNA polymerase I promoter operably linked to an influenza virus PB2 cDNA linked to a RNA polymerase I transcription termination sequence,

a vector comprising a RNA polymerase I promoter operably linked to an influenza virus NP cDNA linked to a RNA polymerase I transcription termination sequence,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NP polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus HA polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NA polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus M1 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus M2 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NS2 polypeptide, and

a vector comprising a RNA polymerase I promoter linked to 5' non-coding influenza virus sequences linked to an antisense cDNA linked to 3' non-coding influenza virus sequences linked to a RNA polymerase I transcription termination sequence,

and isolating the infectious influenza virus.

2. A cell transfected with a plurality of orthomyxovirus vectors, said vectors comprising:

a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2 polypeptide,

a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus NP polypeptide, and

a vector comprising a promoter linked to 5' non-coding influenza virus sequences linked to an antisense cDNA of interest or a fragment thereof in antisense orientation linked to 3' non-coding influenza virus sequences linked to a transcription termination sequence,

wherein the cell transfected does not comprise a helper virus, and

wherein said preparation is isolated from said cells.

3. A method for producing infectious recombinant influenza virus in the absence of helper virus, comprising the step of introducing into a cell a composition comprising a plurality of orthomyxovirus vectors, which are sufficient to produce infectious recombinant influenza viruses, said vectors comprising:

(i) a vector comprising a promoter operably linked to an influenza virus PA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB1 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus PB2 cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus HA cDNA linked to a transcription termination sequence, a vector

comprising a promoter operably linked to an influenza virus NP cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus NA cDNA linked to a transcription termination sequence, a vector comprising a promoter operably linked to an influenza virus M cDNA linked to a transcription termination sequence, and a vector comprising a promoter operably linked to an influenza virus NS cDNA linked to a transcription termination sequence,

(ii) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PA,

(iii) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB1,

(iv) a vector comprising a promoter operably linked to a DNA segment encoding an influenza virus PB2, and

(v) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NP.

4. The method of claim 3, wherein said plurality of orthomyxovirus vectors further comprises:

(vi) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus HA,

(vii) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NA,

(viii) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M1,

(ix) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus M2, and

(x) a vector comprising a promoter operably linked to a DNA segment encoding influenza virus NS2.

5. The method of claim 3 or 4, wherein said vectors further comprise a vector comprising a promoter linked to 5' non-coding influenza virus sequences linked to a cDNA of interest or a fragment thereof in antisense orientation linked to 3' non-coding influenza virus sequences linked to a transcription termination sequence.
6. The method of claim 3 or 4 further comprising isolating the infectious recombinant influenza virus.
7. The method of claim 5 further comprising isolating the infectious recombinant influenza virus.
8. The method of claim 5 in which the cDNA of interest or the fragment thereof in antisense orientation encodes a therapeutic protein.
9. The method of claim 5 in which the cDNA of interest or the fragment thereof in antisense orientation encodes an immunogenic protein.
10. The method according to claim 3 or 4 wherein the vectors which comprise cDNA are linked.
11. The method according to claim 3 or 4 wherein the vectors which encode viral proteins are linked.
12. The method according to claim 3 or 4 wherein each influenza virus cDNA is on a separate vector.
13. The method according to claim 3 or 4 wherein each DNA segment encoding an influenza viral protein is on a separate vector.
14. The method according to claim 3 or 4 wherein the promoter of the vectors of (i) comprise a RNA polymerase I promoter, RNA polymerase H promoter, RNA polymerase III promoter, T7 promoter, or T3 promoter.
15. The method according to claim 14 wherein the RNA polymerase I promoter is a human RNA polymerase I promoter.

16. The method according to claim 3 or 4 wherein the vectors encoding a viral protein further comprise a RNA transcription termination sequence.
17. The method according to claim 3 or 4 wherein the transcription termination sequence of the vectors of (i) comprise a RNA polymerase I transcription termination sequence, RNA polymerase II transcription termination sequence, RNA polymerase III transcription termination sequence, or a ribozyme.

1/15




FIG. 1





FIG. 2











FIG. 4

5/15




FIG. 5

PoliI-5'WPB2

CAC ACA CGT CTC GTA TTA GTA GAA ACA AGG TCG TTT TTA AAC TAT TCG
 ACA CTA ATT GAT GGC CAT CCG AAT TCT TTT GG

Length: 80 nt

Overlap: 26 nt

PoliI-3'WPB2

CAC ACA CGT CTC CGG GAG CGA AAG CAG GTC AAT TAT ATT CAA TAT GGA
 AAG AAT AAA AGA ACT AAG G

Length: 67 nt

Overlap: 24 nt

PoliI-5'WPB1

CAC ACA CGT CTC GTA TTA GTA GAA ACA AGG CAT TTT TTC ATG AAG GAC
 AAG CTA AAT TCA CTA TTT TTG CCG TCT GAG CTC TTC AAT GG

Length: 89

Overlap: 26 nt

PoliI-3'WPB1

CAC ACA CGT CTC CGG GAG CGA AAG CAG GCA AAC CAT TTG AAT GGA TGT
 CAA TCC GAC TTT ACT TTT C

Length: 67 nt

Overlap: 27 nt

PoliI-5'WPA

CCA ACC CGT CTC CTA TTA GTA GAA ACA AGG TAC TTT TTT GGA CAG TAT
 GGA TAG CAA ATA GTA GCA TTG CCA CAA CTA TCT CAA TGC ATG TGT GAG
 GAA GGA G

Length: 103

Overlap: 25 nt

PoliI-3'WPA

CCA ACC CGT CTC CGG GAG CGA AAG CAG GTA CTG ATT CAA AAT GGA AGA
 TTT TGT GCG ACA ATG CTT C

Length: 67 nt

Overlap: 27 nt

PoliI-5'WHA

CAC ACA CGT CTC CTA TTA GTA GAA ACA AGG GTG TTT TTC C

Length: 40 nt

Overlap: 22 nt

PoliI-3'WHA

CAC ACA CGT CTC CGG GAG CAA AAG CAG GGG AAA AT AAA AAC AAC C

Length: 46 nt

Overlap: 29 nt

FIG. 6A

Poli-5'WNP

CAC ACA CGT CTC CTA TTA GTA GAA ACA AGG GTA TTT TTC TTT AAT TG

Length: 47 nt

Overlap: 30 nt

Poli-3'WNP

CAC ACA CGT CTC CGG GAG CAA AAG CAG GGT AGA TAA TCA CTC

Length: 42 nt

Overlap: 26 nt

Poli-5'WNA

CAC ACA CGT CTC CTA TTA GTA GAA ACA AGG AGT TTT TTG AAC AAA C

Length: 46 nt

Overlap: 29 nt

Poli-3'WNA

CAC ACA CGT CTC CGG GAG CGA AAG CAG GAG TTT AAA TGA ATC CAA ACC

Length: 48 nt

Overlap: 32 nt

Poli-5'WM

CAC ACA CGT CTC CTA TTA GTA GAA ACA AGG TAG TTT TTT ACT CCA GC

Length: 47 nt

Overlap: 30 nt

Poli-3'WM

CAC ACA CGT CTC CGG GAG CAA AAG CAG GTA GAT ATT GAA AG

Length: 41 nt

Overlap: 26 nt

Poli-5'WNSCAC ACA CGT CTC CTA TTA GTA GAA ACA AGG GTG TTT TTT ATT ATT AAA
TAA GC

Length: 53 nt

Overlap: 36 nt

Poli-3'WNS

CAC ACA CGT CTC CGG GAG CAA AAG CAG GGT GAC AAA GAC ATA ATG G

Length: 46 nt

Overlap: 30 nt

Italics: BsmBI recognition sequence
 Underlined: Influenza virus sequence
 Underlined + Bold: Influenza virus coding region

FIG. 6B




FIG. 7

PLASMID FOR VIRUS-LIKE RNA




FIG. 8




FIG. 9A

11/15




FIG. 9B



FIG. 10A

13/15



FIG. 10B




FIG. 11

15/15




FIG. 12

PLASMID FOR VIRUS-LIKE RNA

